Investigators conducted a pilot clinical trial of a humanized CD19 CAR T-cell product in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia or B-lymphoblastic lymphoma, treated in two cohorts: with or without prior CAR exposure.
[Journal of Clinical Oncology]
7992332
XPGPHHV6
items
1
apa
0
default
asc
1
163779
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
